Related Experiment Video
Updated: Jun 11, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Metabolic and renal factors associated with plasma phosphorylated tau analytes used to detect Alzheimer's disease
Kao Lee Yang1, Yue Ma1, Gilda Ennis1
1Wisconsin Alzheimer's Disease Research Center University of Wisconsin Madison Wisconsin USA.
Introduction:
We examined the extent to which insulin resistance (IR), type 2 diabetes mellitus, obesity, and kidney function are associated with plasma phosphorylated tau (p-tau) concentrations (p-tau181, p-tau217, p-tau231) in the same cohort and the contribution of these factors on amyloid positron emission tomography (PET) concordance and longitudinal p-tau levels.
Methods:
We analyzed data from 287 participants using partial Spearman rho, Mann-Whitney U, receiver operating characteristic analysis, and linear mixed models.
Results:
Concordance between plasma p-tau217 and amyloid PET was not influenced by IR or estimated glomerular filtration rate (eGFR). Accounting for eGFR improved concordance of p-tau181 and p-tau231 with amyloid PET. Age, binarized waist-to-hip ratio, and amyloid status were associated with all longitudinal p-tau concentrations, and eGFR associated with longitudinal p-tau231.
Discussion:
Metabolic factors may influence the interpretation of longitudinal plasma p-tau concentrations and kidney function may influence amyloid PET concordance for p-tau181 and p-tau231, potentially necessitating analyte-specific adjustments or considerations in clinical interpretation.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
